Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia® as Biological Intensive Treatment for RA (ORBIT) study

Modern Rheumatology

Volumn 24, Issue 5, 2014, Pages 754-762

  Tanaka, Yoshiya ^a   Kubo, Satoshi ^a   Yamanaka, Hisashi ^b   Amano, Koichi ^c   Hirata, Shintaro ^a   Tanaka, Eiichi ^b   Nagasawa, Hayato ^c   Yasuoka, Hidekata ^d   Takeuchi, Tsutomu ^d  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Abatacept; Joint destruction; Remission; Retrospective study; Rheumatoid arthritis

Indexed keywords

ABATACEPT; METHOTREXATE; PREDNISOLONE; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; COMPRESSION FRACTURE; DAS28; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAIR LOSS; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SECRETORY OTITIS MEDIA; SIMPLIFIED DISEASE ACTIVITY INDEX; SKIN ULCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS; AGED; ARTHRITIS, RHEUMATOID; DISEASE COURSE; FOOT; HAND JOINT; RADIOGRAPHY;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; FOOT JOINTS; HAND JOINTS; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84906313840     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.872862     Document Type: Article

References (45)

1. Bankhurst AD, Husby G, Williams RC Jr. Predominance of T cells in the lymphocytic infi ltrates of synovial tissues in rheumatoid arthritis. Arthritis Rheum. 1976;19(3):555-62.
2. Cush JJ, Lipsky PE. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum. 1988;31(10):1230-8.
3. Fox R.I, Fong S, Sabharwal N, Carstens S.A, Kung P.C, Vaughan J H. Synovial fl uid lymphocytes diff er from peripheral blood lymphocytes in patients with rheumatoid arthritis. J Immunol. 1982;128(1):351-4.
4. Van Boxel J.A, Paget S A. Predominantly T-cell infi ltrate in rheumatoid synovial membranes. N Engl J Med. 1975; 293(11): 517-20. doi:10.1056/ nejm197509112931101.
5. Kremer J M. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin North Am. 2004; 30(2): 381-91, viii. doi:10.1016/j.rdc.2004.02.002.
6. Korhonen R, Moilanen E. Abatacept, anovel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104(4):276-84. doi:10.1111/ j.1742-7843.2009.00375.x.
7. Guyot P, Taylor PC, Christensen R, Pericleous L, Drost P, Eijgelshoven I, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol. 2012; 39(6): 1198-206. doi:10.3899/jrheum.111345.
8. Kremer J.M, Genant H.K, Moreland L.W, Russell A.S, Emery P, Abud-Mendoza C, et al. Eff ects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2006;144(12):865-76.
9. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-Term safety, Efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826-30. doi:10.1136/ard.2010.139345.
10. Li T, Gignac M, Wells G, Shen S, Westhovens R. Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clin Ther. 2008; 30(4): 734-48.
11. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infl iximab vs placebo in ATTEST: A phase III, multi-centre, randomised, doubleblind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096-103. doi:10.1136/ard.2007.080002.
12. Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. 2013; 23(2): 226-35. doi:10.1007/ s10165-012-0668-z.
13. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005; 353(11): 1114-23. doi:10.1056/NEJMoa050524.
14. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-Tumour necrosis factor therapy. Ann Rheum Dis. 2008; 67(4): 547-54. doi:10.1136/ ard.2007.074773.
15. Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, Dougados M. Longterm safety and Efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol. 2012; 39(8): 1546-54. doi:10.3899/ jrheum.111531.
16. Schiff M, Pritchard C, Huff stutter J.E, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and Efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-Tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708-14. doi:10.1136/ard.2008.099218.
17. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical Efficacy and safety of abatacept in methotrexatenaive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009; 68(12): 1870-7. doi:10.1136/ard.2008. 101121.
18. Yazici Y, Moniz Reed D, Klem C, Rosenblatt L, Wu G, Kremer JM. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: A post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol. 2011;29(3):494-9.
19. Emery P, Durez P, Dougados M, Legerton C.W, Becker J.C, Vratsanos G, et al. Impact of T-cell costimulation modulation in patients with undiff erentiated infl ammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69(3):510-6. doi:10.1136/ ard.2009.119016.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
21. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classifi cation of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35(5):498-502.
22. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012; 64(5): 640-7. doi:10.1002/acr.21649.
23. Felson DT., Smolen J.S, Wells G, Zhang B, Van Tuyl L.H, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional defi nition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573-86. doi:10.1002/ art.30129.
24. Fries J.F, Spitz P, Kraines R.G, Holman H R. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-45.
25. Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784-8. doi:10.1002/art.11465.
26. Van Der Heijde D. How to read radiographs according to the Sharp/Van Der Heijde method. J Rheumatol. 2000;27(1):261-3.
27. Weinblatt M, Combe B, Covucci A, Aranda R, Becker J.C, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807-16. doi:10.1002/art.22070.
28. Cascao R, Moura R.A, Perpetuo I, Canhao H, Vieira-Sousa E, Mourao AF, et al. Identifi cation of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R196. doi:10.1186/ar3168.
29. Rasmussen TK, Andersen T, Hvid M, Hetland ML, Horslev-Petersen K, Stengaard-Pedersen K, et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol. 2010;37(10):2014-20. doi:10.3899/ jrheum.100259.
30. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable Efficacy and related factors of infl iximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18(2):146-52. doi:10.1007/ s10165-008-0026-3.
31. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawat AM, Nagasawa H, et al. Clinical, radiographic and functional eff ectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology (Oxford). 2011; 50(10): 1908-15. doi:10.1093/rheumatology/ker221.
32. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2013-204573.
33. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann Rheum Dis. 2010; 69(6): 964-75. doi:10.1136/ard.2009.126532.
34. Gottenberg J.E, Ravaud P, Cantagrel A, Combe B, Flipo R.M, Schaeverbeke T, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: Data from the ' Orencia and Rheumatoid Arthritis ' registry. Ann Rheum Dis. 2012;71(11):1815-9. doi:10.1136/annrheumdis-2011- 201109.
35. Cohen S.B, Emery P, Greenwald M.W, Dougados M, Furie R.A, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-Tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary Efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-806. doi:10.1002/art.22025.
36. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al.; DANCER Study Group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5): 1390-400. doi:10.1002/art. 21778.
37. Kremer J.M, Genant H.K, Moreland L.W, Russell A.S, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008; 58(4): 953-63. doi:10.1002/art.23397.
38. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infl iximab or abatacept: Open-label extension of the ATTEST Study. Ann Rheum Dis. 2011;70(11):2003-7. doi:10.1136/annrheumdis-2011-200316.
39. Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011;70(11):1949-56. doi:10.1136/ard.2010.145268.
40. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, et al. Eff ectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: Retrospective analyses of data collected during the fi rst year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 2012; 22(3): 327-38. doi:10.1007/s10165-011-0516-6.
41. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawat AM, Ikari K, et al. Retrospective clinical study on the notable Efficacy and related factors of infl iximab therapy in a rheumatoid arthritis management group in Japan: One-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008;18(5):447-54. doi:10.1007/ s10165-008-0077-5.
42. Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, et al. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Mod Rheumatol. 2012;22(2):186-94. doi:10.1007/s10165-0110510-z.
43. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21(2):122-33. doi:10.1007/s10165-010-0366- 7.
44. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable Efficacy and related factors of infl iximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17(1):28-32. doi:10.1007/s10165-006-0532-0.
45. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008;67(11):1603-9. doi:10.1136/ard.2007.080713.